Traitements2programmes
Essais1liés
Publications0liées
SourceDBlocale

Traitements

2
MoléculeIndication / populationPhaseObjectifPaysRésultat
RebifThe purpose of this trial is to evaluate the effects of Rebif® 44 mcg subcutaneous (sc) three times a week (tiw) on a) remyelination/demyelination, b) lesion and brain volume, c) central nervous system (CNS) iron deposition, and d) immune status in subjects with relapsing-remitting multiple sclerosis (RRMS) RRMS via several MRI techniques. SEP Phase 4 Remyélinisation United States À vérifier
RebifThe purpose of this trial is to evaluate the effects of Rebif® 44 mcg subcutaneous (sc) three times a week (tiw) on a) remyelination/demyelination, b) lesion and brain volume, c) central nervous system (CNS) iron deposition, and d) immune status in subjects with relapsing-remitting multiple sclerosis (RRMS) RRMS via several MRI techniques. SEP Phase 4 Remyélinisation United States À vérifier

Essais cliniques

1
MoléculeIndication / populationPhaseNCTTitreStatut
Rebif SEP Phase 4 NCT01085318 Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial COMPLETED

Publications

0
MoléculeIndication / populationTitreJournalDate
Aucune publication.